TY - JOUR
T1 - Plasma biomarkers of tubular injury and inflammation are associated with CKD progression in children
AU - Greenberg, Jason H.
AU - Abraham, Alison G.
AU - Xu, Yunwen
AU - Schelling, Jeffrey R.
AU - Feldman, Harold I.
AU - Sabbisetti, Venkata S.
AU - Gonzalez, Mariana Cardenas
AU - Coca, Steven
AU - Schrauben, Sarah J.
AU - Waikar, Sushrut S.
AU - Ramachandran, Vasan S.
AU - Shlipak, Michael G.
AU - Warady, Bradley
AU - Kimmel, Paul L.
AU - Bonventre, Joseph V.
AU - Denburg, Michelle
AU - Parikh, Chirag R.
AU - Furth, Susan
N1 - Funding Information:
Dr. Abraham, Dr. Furth, Dr. Gonzales, Dr. Greenberg, Dr. Kimmel, Dr. Sabbisetti, Dr. Schelling, and Dr. Xu declare no financial interest. Dr. Abraham reports grants from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) during the conduct of the study. Dr. Bonventre is cofounder and holds equity in Goldfinch Bio. He is coinventor on KIM-1 patents assigned to Partners Healthcare, received grant funding from Boehringer In-gelheim, and holds equity in Dicerna, Goldilocks, Innoviva, Medibeacon, Medssenger, Rubius, Sensor-Kinesis, Sentien, Theravance, Thrasos, and VeriNano and has received consulting income from Aldeyra, Angion, Bio-marin, Praxis, PTC, and Sarepta. Dr. Bonventre’s interests were reviewed and are managed by BWH and Partners HealthCare in accordance with their conflict of interest policies. Dr. Coca reports personal fees from Bayer, CHF Solutions, Goldfinch, Janssen, Quark, Relypsa, and Takeda; and personal fees and other from pulseData and RenalytixAI, outside the submitted work. Dr. Feldman reports grants from the National Institutes of Health–NIDDK, during the conduct of the study; and other from the American Journal of Kidney Disease and Kyowa Hakko Kirin Co., Ltd., outside the submitted work. Dr. Parikh reports other from Akebia Therapeutics, Inc., Genfit Biopharmaceutical Company, and Renaltix AI; and grants from the NIDDK and the National Heart, Lung and Blood Institute, outside the submitted work. Dr. Shlipak is a Scientific Advisor for TAI Diagnostics. Dr. Waikar reports personal fees from Barron and Budd (versus Fresenius), Bunch and James, Cerus, CVS, GE Health Care, GSK, Harvard Clinical Research Institute (aka Baim), JNJ, Kantum Pharma, Mallinckrodt, Mass Medical International, Pfizer, the Public Health Advocacy Institute, Roth Capital Partners, Strataca, Takeda, Verbio, Wolters Kluewer; and grants and personal fees from Allena Pharmaceuticals, outside the submitted work.
Funding Information:
This research was supported by National Institutes of Health (NIH) career development grant K08DK110536 (to Dr. Greenberg). Dr. Parikh is supported by NIH K24DK090203, R01HL085757, U01DK082185, and P30DK079310-07 O’Brien Center Grant. Dr. Furth is supported by NIH grants K24DK078737 and U01DK66174. Dr. Schrauben is supported by NIH grant K23DK118198-01A1. Dr. Xu, Dr. Schelling, Dr. Feldman, Dr. Sabbisetti, Dr. Gonzalez, Dr. Coca, Dr. Sabbisetti, Dr. Bonventre, Dr. Parikh, and Dr. Furth receive support from the CKD Biomarkers Consortium (National Institute of Diabetes and Digestive and Kidney Diseases grants U01 DK085689, U01 DK102730, U01 DK103225, and U01 DK085660).
Funding Information:
Data in this manuscript were collected by the CKD in Children prospective cohort study (CKiD) with clinical coordinating centers (Principal Investigators) at Children’s Mercy Hospital and the University of Missouri–Kansas City (Dr. Warady), the Children’s Hospital of Philadelphia (Dr. Furth), and the Central Biochemistry Laboratory (George Schwartz) at the University of Rochester Medical Center, and data coordinating center (Alvaro Muñoz) at the Johns Hopkins Bloomberg School of Public Health. The CKiD study is funded by the National Institute of Diabetes and Digestive and Kidney Diseases, with additional funding from the National Institute of Child Health and Human Development and the National Heart, Lung, and Blood Institute (U01-DK-66143, U01-DK-66174, U01DK-082194, U01-DK-66116). The CKiD website is located at http://www.statepi.jhsph.edu/ckid. The CKD Biomarker consortium members include: Dr. Vasan S. Ramachandran, Dr. Jeffrey Schelling, Dr. Michelle Denburg, Dr. Susan Furth, Dr. Bradley Warady, Dr. Joseph Bonventre, Dr. Sushrut Waikar, Dr. Venkata Sabbisetti, Dr. Josef Coresh, Dr. Morgan Grams, Dr. Casey Rebholz, Dr. Alison Abraham, Dr. Chirag Parikh, Dr. Steven Coca, Dr. Eugene Rhee, Dr. Paul L. Kimmel, Dr. John W. Kusek, Dr. Brad Rovin, Dr. Michael G. Shlipak, Dr. Mark Sarnak, Dr. Orlando M. Gutiérrez, Dr. Joachim Ix, Dr. Ruth Dubin, Dr. Tom Hostetter, Dr. Rajat Deo, Dr. Harold I. Feldman, Dr. Dawei Xie, Dr. Haochang Shou, Mr. Shawn Ballard, Ms. Krista Whitehead, Dr. Heather Collins, Dr. Jason H. Greenberg, and Dr. Peter Ganz.
Publisher Copyright:
© 2020 by the American Society of Nephrology.
PY - 2020/5
Y1 - 2020/5
N2 - Background: After accounting for known risk factors for CKD progression in children, clinical outcomes among children with CKD still vary substantially. Biomarkers of tubular injury (such as KIM-1), repair (such as YKL-40), or inflammation (such as MCP-1, suPAR, TNF receptor-1 [TNFR-1], and TNFR-2) may identify children with CKD at risk for GFR decline. Methods: We investigated whether plasma KIM-1, YKL-40, MCP-1, suPAR, TNFR-1, and TNFR-2 are associated with GFR decline in children with CKD and in subgroups defined by glomerular versus nonglomerular cause of CKD. We studied participants of the prospective CKiD Cohort Study which enrolled children with an eGFR of 30-90 ml/min per 1.73 m2 and then assessed eGFR annually. Biomarkers were measured in plasma collected 5 months after study enrollment. The primary endpoint was CKD progression, defined as a composite of a 50% decline in eGFR or incident ESKD. Results: Of the 651 children evaluated (median age 11 years; median baseline eGFR of 53 ml/min per 1.73 m2), 195 (30%) had a glomerular cause of CKD. Over a median follow-up of 5.7 years, 223 children (34%) experienced CKD progression to the composite endpoint. After multivariable adjustment, children with a plasma KIM-1, TNFR-1, or TNFR-2 concentration in the highest quartile were at significantly higher risk of CKD progression compared with children with a concentration for the respective biomarker in the lowest quartile (a 4-fold higher risk for KIM-1 and TNFR-1 and a 2-fold higher risk for TNFR-2). Plasma MCP-1, suPAR, and YKL-40 were not independently associated with progression. When stratified by glomerular versus nonglomerular etiology of CKD, effect estimates did not differ significantly. Conclusions: Higher plasma KIM-1, TNFR-1, and TNFR-2 are independently associated with CKD progression in children.
AB - Background: After accounting for known risk factors for CKD progression in children, clinical outcomes among children with CKD still vary substantially. Biomarkers of tubular injury (such as KIM-1), repair (such as YKL-40), or inflammation (such as MCP-1, suPAR, TNF receptor-1 [TNFR-1], and TNFR-2) may identify children with CKD at risk for GFR decline. Methods: We investigated whether plasma KIM-1, YKL-40, MCP-1, suPAR, TNFR-1, and TNFR-2 are associated with GFR decline in children with CKD and in subgroups defined by glomerular versus nonglomerular cause of CKD. We studied participants of the prospective CKiD Cohort Study which enrolled children with an eGFR of 30-90 ml/min per 1.73 m2 and then assessed eGFR annually. Biomarkers were measured in plasma collected 5 months after study enrollment. The primary endpoint was CKD progression, defined as a composite of a 50% decline in eGFR or incident ESKD. Results: Of the 651 children evaluated (median age 11 years; median baseline eGFR of 53 ml/min per 1.73 m2), 195 (30%) had a glomerular cause of CKD. Over a median follow-up of 5.7 years, 223 children (34%) experienced CKD progression to the composite endpoint. After multivariable adjustment, children with a plasma KIM-1, TNFR-1, or TNFR-2 concentration in the highest quartile were at significantly higher risk of CKD progression compared with children with a concentration for the respective biomarker in the lowest quartile (a 4-fold higher risk for KIM-1 and TNFR-1 and a 2-fold higher risk for TNFR-2). Plasma MCP-1, suPAR, and YKL-40 were not independently associated with progression. When stratified by glomerular versus nonglomerular etiology of CKD, effect estimates did not differ significantly. Conclusions: Higher plasma KIM-1, TNFR-1, and TNFR-2 are independently associated with CKD progression in children.
UR - http://www.scopus.com/inward/record.url?scp=85084961137&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85084961137&partnerID=8YFLogxK
U2 - 10.1681/ASN.2019070723
DO - 10.1681/ASN.2019070723
M3 - Article
C2 - 32234829
AN - SCOPUS:85084961137
SN - 1046-6673
VL - 31
SP - 1067
EP - 1077
JO - Journal of the American Society of Nephrology
JF - Journal of the American Society of Nephrology
IS - 5
ER -